Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease [Yahoo! Finance]
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech, Inc. (NASDAQ: FBIO) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]